A novel nomogram using PSA mass for predicting BPH

In 2019, there were 94 million cases of benign prostatic hyperplasia globally among men aged 40 years and older. Assessment of prostate volume (PV) is important in evaluating lower urinary tract symptoms and risks in asymptomatic individuals. Serum prostate-specific antigen (PSA) levels have been suggested as a convenient and useful biomarker for benign prostate hyperplasia (BPH). However, studies suggest that using PSA as a biomarker for BPH and prostate cancer can lead to underestimation of disease severity in patients with a high body mass index (BMI). PSA mass has been proposed as a potentially superior predictor compared to total PSA levels. This retrospective study recruited the male patients visiting Kuang Tien General Hospital who had serum PSA level test, underwent transrectal ultrasonography (TRUS) for evaluation of prostate volume between January 2009 and December 2019. PSA mass was obtained by calculating body surface area (BSA) and plasma volume. The data were proved to build a nomogram, to predict the volume of the prostate, and its accuracy was evaluated using internal validation techniques. Statistical analyses were performed using SAS and R. A total of 417 men were included in this study, with a mean age of 67.3 years, mean BMI of 24.9 kg/m2, mean prostate volume of 43.87 mL, mean PSA level of 2.94 ng/mL, and mean PSA mass of 8.68 ng/mL. The results showed that PSA mass had a higher accuracy than PSA in predicting prostate volume, as evidenced by a higher area under curve (AUC) value of 0.8271 for the PSA mass model compared to 0.8218 for the PSA model. Our nomogram showed a satisfying prediction accuracy. PSA mass may be a superior predictor of prostate volume compared to total PSA levels, although only slight improvement was shown.

BPH; PSA; PSA mass; LUTS

[1] GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of disease study 2019. The Lancet Healthy Longevity. 2022; 3: e754–e776.

[2] Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, et al. Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE trial. European Urology. 2016; 69: 885–891.

[3] Awaisu M, Ahmed M, Lawal AT, Sudi A, Tolani MA, Oyelowo N, et al. Correlation of prostate volume with severity of lower urinary tract symptoms as measured by international prostate symptoms score and maximum urine flow rate among patients with benign prostatic hyperplasia. African Journal of Urology. 2021; 27: 1–7.

[4] Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline PART I—initial work-up and medical management. Journal of Urology. 2021; 206: 806–817.

[5] Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014; 311: 1143–1149.

[6] Corona G, Salvi M, Sebastianelli A, Bossa R, Vignozzi L, Maggi M, et al. Role of prostate specific antigen and prostate specific antigen density as biomarkers for medical and surgical treatment response in men with lower urinary tract symptoms. Minerva Urology and Nephrology. 2020; 72: 135–143.

[7] Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53: 581–589.

[8] Chang YL, Lin AT, Chen KK, Chang YH, Wu HH, Kuo JY, et al. Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. Journal of Urology. 2006; 176: 196–199.

[9] Kubota Y, Seike K, Maeda S, Shinohara Y, Iwata M, Sugimoto N. Relationship between prostate-specific antigen and obesity in prostate cancer screening: analysis of a large cohort in Japan. International Journal of Urology. 2011; 18: 72–75.

[10] Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007; 298: 2275–2280.

[11] Vollmer RT. Serum Prostate-specific antigen (PSA) concentration, PSA mass, and obesity. American Journal of Clinical Pathology. 2018; 149: 262–266.

[12] Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, Metter EJ. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore longitudinal study of aging. Journal of Urology. 2009; 182: 2646–2651.

[13] Lin D, Liu T, Chen L, Chen Z. Body mass index in relation to prostate-specific antigen-related parameters. BMC Urology. 2021; 21: 130.

[14] Masuda H, Kawakami S, Sakura M, Fujii Y, Koga F, Saito K, et al. Performance of prostate-specific antigen mass in estimation of prostate volume in Japanese men with benign prostate hyperplasia. International Journal of Urology. 2012; 19: 929–935.

[15] Fowke JH, Matthews CE. PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. The Prostate. 2010; 70: 120–125.

[16] Khan S, Wolin KY, Pakpahan R, Grubb RL, Colditz GA, Ragard L, et al. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia. BMC Urology. 2021; 21: 47.

[17] Chen W, Man S, Wang B, Kadeerhan G, Huang X. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a cohort study of Chinese elderly males. Lower Urinary Tract Symptoms. 2022; 14: 170–177.

[18] Meng J, Liu Y, Guan SY, Ma H, Zhang X, Fan S, et al. Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: evidence from 5285 patients. International Journal of Clinical Practice. 2019; 73: e13438.

[19] Wang YB, Yang L, Deng YQ, Yan SY, Luo LS, Chen P, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. Journal of Translational Medicine. 2022; 20: 495.

[20] Batai K, Phung M, Bell R, Lwin A, Hynes KA, Price E, et al. Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery. BMC Urology. 2021; 21: 88.

[21] Jung JW, Yu YD, Lee YJ, Kim JJ, Lee HM, Oh JJ, et al. Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia? Asian Journal of Andrology. 2018; 21: 86–91.

[22] Berges R, Oelke M. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. World Journal of Urology. 2011; 29: 171–178.

[23] Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. BJU International. 1993; 71: 445–450.

[24] Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. The Prostate. 2007; 67: 1816–1824.

[25] Tsuboi H, Miyamori D, Ishikawa N, Ichioka H, Ikegaya H. Relationship between serum prostate-specific antigen and age in cadavers. SAGE Open Medicine. 2020; 8: 205031212095821.

[26] Ng M, Baradhi KM. Benign prostatic hyperplasia. 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK558920/ (Accessed: 15 May 2023).

[27] Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia—what do we know? BJU International. 2021; 127: 389–399.

[28] Cao N, Lu Q, Si J, Wang X, Ni J, Chen L, et al. The Characteristics of the transitional zone in prostate growth with age. Urology. 2017; 105: 136–140.